دورية أكاديمية
أعرض في EDS

Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.

التفاصيل البيبلوغرافية
العنوان: Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.
المؤلفون: Duran E; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Ozturk ZO; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey., Bilgin E; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey. dr.emrebilgin@gmail.com., Büyükaşık Y; Division of Hematology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey., Dizdar O; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Yardimci GK; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Farisogullari B; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Özsoy Z; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Ayan G; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Uzun GS; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Ekici M; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Unaldi E; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Kilic L; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Akdoğan A; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Karadag O; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Bilgen ŞA; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Kiraz S; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Kalyoncu U; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey., Ertenli AI; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey.
المصدر: Rheumatology and therapy [Rheumatol Ther] 2023 Aug; Vol. 10 (4), pp. 969-981. Date of Electronic Publication: 2023 Jun 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Healthcare Country of Publication: England NLM ID: 101674543 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2198-6576 (Print) Linking ISSN: 21986576 NLM ISO Abbreviation: Rheumatol Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Springer Healthcare, [2014]-
مستخلص: Introduction: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population.
Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR).
Results: Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26-67), and the median age at the HM diagnosis was 55.5 (range, 38-76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35-7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55).
Conclusions: The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.
(© 2023. The Author(s).)
References: Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. (PMID: 10.1016/j.pharmthera.2007.10.00118155297)
Silva LC, Ortigosa LC, Benard GJI. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817–33. (PMID: 10.2217/imt.10.6721091114)
Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55–62. (PMID: 10.1093/intimm/dxu10225411043)
Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2015;64(10):1414–20. (PMID: 10.1136/ard.2004.033241)
Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev. 2010;9(3):175–80. (PMID: 10.1016/j.autrev.2009.07.00619647103)
Chang CC, Chang CW, Nguyen PA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315–22. (PMID: 10.3892/ol.2017.6368287893465529950)
Lee E, Han K-D, Song Y-W, et al. Cancer risk in patients with ankylosing spondylitis: a nationwide population-based dynamic cohort study from Korea. In: Arthritis & rheumatology. Hoboken : Wiley; 2019.
Fantò M, Peragallo MS, Pietrosanti M, et al. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med. 2016;11(1):31–40. (PMID: 10.1007/s11739-015-1270-026099279)
Hagberg KW, Li L, Peng M, et al. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22(5):241–7. (PMID: 10.1097/RHU.0000000000000364268864394966919)
Dreyer L, Mellemkjær L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides—a follow-up study from the DANBIO Registry. Ann Rheum Dis. 2013;72(1):79–82. (PMID: 10.1136/annrheumdis-2012-20196922945500)
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9. (PMID: 10.1002/art.2257917469100)
Greenberg J, Strand V, Keystone E, et al. TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (abstract 282). In: American College of Rheumatology annual meeting. 2007.
Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017;76(1):105–11. (PMID: 10.1136/annrheumdis-2016-20927027147709)
Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 1999;163(10):5358–66. (PMID: 10.4049/jimmunol.163.10.535810553060)
Katschinski DM, Robins HI, Schad M, et al. Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res. 1999;59(14):3404–10. (PMID: 10416602)
Screaton G, Xu XN. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol. 2000;12(3):316–22. (PMID: 10.1016/S0952-7915(00)00093-510781406)
Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503–10. (PMID: 10.1038/nrrheum.2017.8128569267)
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24. (PMID: 10.1002/art.17803103023358796)
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. (PMID: 10.1002/art.2758420872595)
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83. (PMID: 10.1136/ard.2009.10823319297344)
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. (PMID: 10.1002/art.2197216871531)
Turkish National Cancer Registry (TNCR). https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2017-turkiye-kanser-i-statistikleri.html . 2017.
Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648–53. (PMID: 10.1136/ard.2007.08585218467516)
Ballegaard C, Hellgren K, Cordtz R, et al. OP0005 incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries. London: BMJ Publishing Group Ltd; 2019.
Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418–26. (PMID: 10.1124/jpet.301.2.41811961039)
Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50(1):222–9. (PMID: 10.1093/rheumatology/keq36821148156)
Smedby KE, Askling J, Mariette X, et al. Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med. 2008;264(6):514–27. (PMID: 10.1111/j.1365-2796.2008.02029.x19017176)
Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701. (PMID: 10.1002/art.2167516508929)
Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014;43(4):489–97. (PMID: 10.1016/j.semarthrit.2013.08.00324012043)
Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168(4):378–81. (PMID: 10.1001/archinternmed.2007.10718299492)
Alehashemi S, Ward MM. Risk of hematologic malignancies in elderly patients with ankylosing spondylitis: a cohort study and systematic review [published correction appears in Mayo Clin Proc. 2023 Feb 13]. Mayo Clin Proc. 2023;98(1):100–10. (PMID: 10.1016/j.mayocp.2022.06.03036470752)
Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22(5):241–7. (PMID: 10.1097/RHU.0000000000000364268864394966919)
فهرسة مساهمة: Keywords: Hematologic malignancy; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis; TNF inhibitors
تواريخ الأحداث: Date Created: 20230609 Latest Revision: 20231113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10326223
DOI: 10.1007/s40744-023-00563-z
PMID: 37294405
قاعدة البيانات: MEDLINE
الوصف
تدمد:2198-6576
DOI:10.1007/s40744-023-00563-z